A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Nipocalimab (Primary) ; Antimalarials; Immunomodulators
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 13 Dec 2023 Planned primary completion date changed from 10 Dec 2024 to 2 May 2024.
- 05 Dec 2023 Planned End Date changed from 10 Dec 2024 to 26 Dec 2024.
- 05 Dec 2023 Status changed from recruiting to active, no longer recruiting.